Description: 89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Home Page: www.89bio.com
ETNB Technical Analysis
142 Sansome Street
San Francisco,
CA
94104
United States
Phone:
415 432 9270
Officers
| Name | Title |
|---|---|
| Mr. Rohan Palekar | CEO & Director |
| Mr. Quoc Le-Nguyen | Chief Technical Operations Officer & Head of Quality |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Mr. Ryan Stephen Martins | Chief Financial Officer |
| Mr. Shiva K. Natarajan | Sr. VP of Fin. & Principal Accounting Officer |
| Ms. Melissa Abel | Sr. VP of Commercial Strategy & Communications |
| Ms. Amanda Hill | VP of People & Culture |
| Ms. Yun Bai | VP & Head of CMC |
| Mr. Paul Shin | Sr. VP of R&D Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1111 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-11-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |